Cellectar Biosciences (CLRB) Projected to Post Earnings on Tuesday

Cellectar Biosciences (NASDAQ:CLRB) is expected to issue its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($1.8850) per share and revenue of $8.00 million for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:30 AM ET.

Cellectar Biosciences (NASDAQ:CLRB) last released its earnings results on Wednesday, March 4th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($1.19) by $0.66. On average, analysts expect Cellectar Biosciences to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Cellectar Biosciences Trading Up 26.9%

CLRB traded up $0.76 on Tuesday, hitting $3.59. 50,916,908 shares of the company were exchanged, compared to its average volume of 650,851. Cellectar Biosciences has a twelve month low of $2.43 and a twelve month high of $20.60. The company has a market cap of $15.23 million, a price-to-earnings ratio of -0.37 and a beta of 0.43. The firm has a 50-day moving average price of $2.92 and a two-hundred day moving average price of $3.22.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE boosted its position in shares of Cellectar Biosciences by 25.3% during the 4th quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 41,704 shares in the last quarter. DRW Securities LLC lifted its holdings in shares of Cellectar Biosciences by 114.2% in the 4th quarter. DRW Securities LLC now owns 45,190 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 24,089 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Cellectar Biosciences by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 28,636 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 3,744 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Cellectar Biosciences in the 3rd quarter valued at about $104,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Cellectar Biosciences in the 3rd quarter valued at about $73,000. 16.41% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CLRB has been the subject of several analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Cellectar Biosciences in a research note on Monday, April 20th. Roth Mkm reissued a “buy” rating and set a $11.00 target price on shares of Cellectar Biosciences in a research note on Tuesday. Finally, Maxim Group raised Cellectar Biosciences from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $11.00.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma.